Rhee 2013 98 Korea Randomized 6 mth Anastrozole or letrozole Low dose alendronate + vitamin D3, Alendronate and calcitrol placebo-controlled (24 All pts 500 mg calcium & 400 vitamin Placebo double-blind wks) D, 24 weeks treatment Van Poznak 234 US Open-label high risk, 24 Anastrozole 1 mg/day Risedronate 35 mg/wk oral High risk – risedronate 2010 SABRE randomized med (37% prior Tamoxifen) Calcium 1000 mg/day + vitamin D Med risk – risedronate risk, double-blind, 400 IU/day Med risk – placebo phase III/IV Low risk– no bone tx Ellis 2009 302 US + Canada (53 Randomized phase 24 Letrozole or Anastrozole Denosumab (subcutaneous 60 mg, 6 Denosumab sites) III open-label trial (in 73%), Exemestane (in mths, 4 doses) Placebo 11%) Calcium + Vitamin D 400 IU/day Phase II, Anastrozole (already on Vitamin D2 high dose 50,000 IU 60 US 6 High dose vitamin D2 randomized, for 15-21 months) every 8 or 16 weeks, 24 weeks Rastelli 2011 Placebo treatment Martyn St 442 UK Meta-analysis of varied Not applicable. Sedentary Exercise protocol that included any Exercise group James 2009 RCTs post-menopausal women. running or jumping movements with Control or without resistance training
Rhee 2013 98 Korea Randomized placebo-controlled double-blind 6 mth (24 wks) Anastrozole or letrozole Low dose alendronate + vitamin D3, All pts 500 mg calcium & 400 vitamin D, 24 weeks treatment Alendronate and calcitrol Placebo Van Poznak 2010 SABRE 234 US Open-label high risk, randomized med risk, double-blind, phase III/IV 24 Anastrozole 1 mg/day (37% prior Tamoxifen) Risedronate 35 mg/wk oral Calcium 1000 mg/day + vitamin D 400 IU/day High risk – risedronate Med risk – risedronate Med risk – placebo Low risk– no bone tx Ellis 2009 302 US + Canada (53 sites) Randomized phase III open-label trial 24 Letrozole or Anastrozole (in 73%), Exemestane (in 11%) Denosumab (subcutaneous 60 mg, 6 mths, 4 doses) Calcium + Vitamin D 400 IU/day Denosumab Placebo Rastelli 2011 60 US Phase II, randomized, 6 Anastrozole (already on for 15-21 months) Vitamin D2 high dose 50,000 IU every 8 or 16 weeks, 24 weeks treatment High dose vitamin D2 Placebo Martyn St James 2009 442 UK Meta-analysis of RCTs varied Not applicable. Sedentary post-menopausal women. Exercise protocol that included any running or jumping movements with or without resistance training Exercise group Control